Dual HER2 Blockade: Preclinical and Clinical Data

Breast Cancer Research - United Kingdom
doi 10.1186/s13058-014-0419-5
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Dual Fatty Acid Synthase and HER2 Signaling Blockade Shows Marked Antitumor Activity Against Breast Cancer Models Resistant to Anti-Her2 Drugs

PLoS ONE
Multidisciplinary
2015English

Neue Wege Bei Der HER2-Blockade

InFo Onkologie
2017English

The Preclinical Profile of the Duocarmycin-Based HER2-Targeting ADC SYD985 Predicts for Clinical Benefit in Low HER2-Expressing Breast Cancers

Molecular Cancer Therapeutics
Cancer ResearchOncology
2015English

Preclinical and Clinical Data for Factor Xa and “Universal” Reversal Agents

American Journal of Medicine
Medicine
2016English

Dual HER2 Blockade Versus a Single Agent in Trastuzumab-Containing Regimens for HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Journal of Oncology
Oncology
2020English

Sequential HER2 Blockade as Effective Therapy in Chemorefractory, HER2 Gene-Amplified, RAS Wild-Type, Metastatic Colorectal Cancer: Learning From a Clinical Case

ESMO Open
Cancer ResearchOncology
2018English

Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): From Preclinical Experiments Towards Possible Clinical Anticancer Applications

Journal of Cancer
Oncology
2013English

Dual PI3K/mTORC1 Targeting Suppresses HER2+ Brain Metastasis Xenografts

Cancer Discovery
Oncology
2016English

Predictability in Psychopharmacology: Preclinical and Clinical Correlations

BMJ
1976English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy